e-Tumour - Web Accessible MR Decision Support System For Brain Tumour Diagnosis And Prognosis, Incorporating In Vivo and Ex Vivo Genomic and Metabolomic Data
From 01-02-2004 to 31-07-2009
Website: http://www.etumour.net/
Description
Diagnosis and treatment of brain tumors is based on clinical symptoms, the radiological appearance by Magnetic Resonance Imaging (MRI), and frequently a histopathological diagnosis of a biopsy. However, treatment response of histological or radiologically similar tumors can vary widely, particularly for childhood tumors. New technologies have become available that may greatly improve tumor classification in terms of diagnosis and prognosis, and may allow individually optimized treatments. 1H MR Spectroscopy (MRS) is a non-invasive technique providing information on the biochemicals present (the metabolomic profile) in a tumor. 1H MRS is performed in conjunction with a clinical MRI but widespread use is hampered by specialised analysis requirements and poor dissemination of the skills needed to interpret the data. The genomic profile of tumors can be deteremined with DNA microarrays. We will bring together the expertise required for a large-scale study of the genomic and metabolomic characteristics of brain tumors, with a multi-centre collaboration to acquire statistically significant data, particularly for rare tumor types. In vivo clinical MRS, high-resolution magic angle spinning (HR MAS) 1H MRS of biopsy samples, and gene array analysis, will be used to investigate how metabolomic and genomic profiles relate to clinically relevant factors such as survival time and treatment response.
Team
- Sabine Van Huffel, Promoter
Financing
Funding: EU Funding - European Funding
Program/Grant Type: EU Other - Other
Events
2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery
3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery
12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers
News
STADIUS Alumni Herman Verrelst – new CEO of Biocartis
08 June 2017
Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.
Supporting healthcare policymaking via machine learning – batteries included!
29 May 2017
STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.
Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"
10 February 2017
Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?
Joos Vandewalle is nieuwe voorzitter KVAB
09 October 2016
Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.